• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Altria Group Inc.

    8/4/25 4:58:18 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    FWP 1 d53673dfwp.htm FWP FWP

    Filed Pursuant to Rule 433

    Registration No. 333-275173

    FINAL TERM SHEET

    Dated August 4, 2025

    4.500% Notes due 2030

    5.250% Notes due 2035

     

    Issuer:    Altria Group, Inc.
    Guarantor:    Philip Morris USA Inc.
    Aggregate Principal Amount:   

    2030 Notes: $500,000,000

    2035 Notes: $500,000,000

    Maturity Date:   

    2030 Notes: August 6, 2030

    2035 Notes: August 6, 2035

    Coupon:   

    2030 Notes: 4.500%

    2035 Notes: 5.250%

    Interest Payment Dates:   

    2030 Notes: Semi-annually on February 6 and August 6, commencing February 6, 2026

    2035 Notes: Semi-annually on February 6 and August 6, commencing February 6, 2026

    Price to Public:   

    2030 Notes: 99.558% of principal amount

    2035 Notes: 99.447% of principal amount

    Benchmark Treasury:   

    2030 Notes: 3.875% UST due July 31, 2030

    2035 Notes: 4.250% UST due May 15, 2035

    Benchmark Treasury Yield:   

    2030 Notes: 3.750%

    2035 Notes: 4.202%

    Spread to Benchmark Treasury:   

    2030 Notes: +85 bps

    2035 Notes: +112 bps

    Yield to Maturity:   

    2030 Notes: 4.600%

    2035 Notes: 5.322%

    Optional Redemption:    2030 Notes: Make-whole call at T+15 bps prior to July 6, 2030; par call on or after July 6, 2030


       2035 Notes: Make-whole call at T+20 bps prior to May 6, 2035; par call on or after May 6, 2035
    Trade Date:    August 4, 2025
    Settlement Date (T+2*):    August 6, 2025
    CUSIP / ISIN:   

    2030 Notes: CUSIP: 02209S BU6

    ISIN: US02209SBU69

     

    2035 Notes: CUSIP: 02209S BV4

    ISIN: US02209SBV43

    Listing:    None.
    Joint Book-Running Managers:   

    Barclays Capital Inc.

    Citigroup Global Markets Inc.

    Goldman Sachs & Co. LLC

    J.P. Morgan Securities LLC

    Senior Co-Managers:   

    Deutsche Bank Securities Inc.

    Mizuho Securities USA LLC

    Morgan Stanley & Co. LLC

    PNC Capital Markets LLC

    Santander Investment Securities Inc.

    Scotia Capital (USA) Inc.

    U.S. Bancorp Investments, Inc.

    Wells Fargo Securities, LLC

    Co-Managers:   

    Academy Securities, Inc.

    Siebert Williams Shank & Co., LLC

     

     

    The issuer has filed a registration statement (including a prospectus) and a preliminary prospectus supplement each with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, that preliminary prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the preliminary prospectus supplement upon your request by calling Barclays Capital Inc. toll free at 1-888-603-5847; Citigroup Global Markets Inc. toll free at 1-800-831-9146; Goldman Sachs & Co. LLC toll free at 1-866-471-2526; or J.P. Morgan Securities LLC collect at 1-212-834-4533.

     

    *

    We expect that delivery of the notes will be made against payment therefor on August 6, 2025, which will be the second business day following the trade date (such settlement being referred to as “T+2”). Under Rule 15c6-l under the Securities Exchange Act of 1934, as amended, trades in the secondary market are required to settle in one business day, unless


    the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes more than one business day prior to the delivery of the notes will be required, by virtue of the fact that the notes initially settle in T+2, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes during such period should consult their own advisors.

    Get the next $MO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    7/9/2025$50.00Underperform
    Jefferies
    7/2/2025$59.00Sell → Neutral
    UBS
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    More analyst ratings

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altria Reports 2025 Second-Quarter and First-Half Results; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 second-quarter and first-half business results and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses," said Billy Gifford, Altria's Chief Executive Officer. "In oral tobacco, on! delivered strong performance and was the substantial driver of the segment's growth in the quarter. And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases." "We are raising the lower-end of ou

    7/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast of 2025 Second-Quarter and First-Half Results

    Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 second-quarter and first-half business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com. During the webcast, Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Chief Financial Officer, will discuss the Company's 2025 second-quarter and first-half business results and answer questions from the investment community and news media. The webcast will be in a listen-only mode. Pre-event registration is neces

    7/16/25 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

    5/15/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Patterson Katie F claimed ownership of 17,191 shares (SEC Form 3)

    3 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    8/1/25 2:37:57 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Yzaguirre Mario Max was granted 3,219 shares, increasing direct ownership by 25% to 16,252 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:06:43 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Strahlman Ellen R was granted 3,219 shares, increasing direct ownership by 16% to 23,087 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:05:17 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Altria with a new price target

    Jefferies resumed coverage of Altria with a rating of Underperform and set a new price target of $50.00

    7/9/25 8:26:04 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

    7/2/25 7:43:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria downgraded by Deutsche Bank

    Deutsche Bank downgraded Altria from Buy to Hold

    4/1/25 3:04:54 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    SEC Filings

    View All

    SEC Form 8-K filed by Altria Group Inc.

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    8/6/25 4:57:40 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form FWP filed by Altria Group Inc.

    FWP - ALTRIA GROUP, INC. (0000764180) (Subject)

    8/4/25 4:58:18 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Altria Group Inc.

    10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

    7/30/25 7:22:57 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:08:44 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:03:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    View All

    Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

    Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

    2/26/24 4:30:00 PM ET
    $ARIS
    $MO
    $PXD
    Oilfield Services/Equipment
    Energy
    Medicinal Chemicals and Botanical Products
    Health Care

    Seasoned Financial Expert Max Yzaguirre Named Strategic Advisor of FireFly Automatix, Leader in AV and EV-Driven Professional Turfgrass Mowing Technology

    -Yzaguirre joins a list of seasoned professionals on FireFly's team with specific expertise in initiating and growing businesses in evolving market conditions- FireFly Automatix, Inc., the de facto industry leader in AV and EV professional turfgrass mowing technology, today announced the appointment of financial and leadership expert M. Max Yzaguirre as a strategic advisor to CEO Andrew Limpert and the board of directors. Yzaguirre's appointment follows the recent additions of former WPP Group CFO Paul Richardson and capital markets professional Liz Hocker to FireFly's board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202401

    1/23/24 9:00:00 AM ET
    $ARIS
    $LBC
    $MO
    Oilfield Services/Equipment
    Energy
    Major Banks
    Finance

    Altria Group, Inc. Announces Retirement of Director Nabil Y. Sakkab From Board of Directors

    Nabil Y. Sakkab, a director of Altria Group, Inc. ("Altria") since 2008, will retire from service on our Board of Directors following the completion of his current term. Consequently, Mr. Sakkab will not stand for re-election to the Board of Directors at Altria's 2024 Annual Meeting of Shareholders, which Altria anticipates holding on May 16, 2024. "Nabil's contributions have significantly benefited Altria over the past 15 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank him for his long and distinguished service and wish him the very best upon his retirement." Dr. Sakkab is Chair of the Innovation Committee and is a member of the Executive, Finance, and

    10/25/23 4:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Financials

    Live finance-specific insights

    View All

    Altria Reports 2025 Second-Quarter and First-Half Results; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 second-quarter and first-half business results and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses," said Billy Gifford, Altria's Chief Executive Officer. "In oral tobacco, on! delivered strong performance and was the substantial driver of the segment's growth in the quarter. And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases." "We are raising the lower-end of ou

    7/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

    5/15/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

    4/29/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/24 4:58:48 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/23 2:49:28 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/9/23 10:54:46 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care